Swiss National Bank Grows Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Swiss National Bank grew its position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 115,400 shares of the company's stock after acquiring an additional 31,200 shares during the period. Swiss National Bank owned about 0.12% of Scholar Rock worth $4,988,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired a new position in Scholar Rock in the 3rd quarter worth about $202,000. Charles Schwab Investment Management Inc. lifted its position in shares of Scholar Rock by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock valued at $4,027,000 after buying an additional 42,139 shares in the last quarter. Fisher Asset Management LLC grew its stake in Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock valued at $5,879,000 after acquiring an additional 628,186 shares during the period. FMR LLC increased its holdings in Scholar Rock by 3.1% in the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company's stock worth $81,670,000 after acquiring an additional 308,813 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Scholar Rock by 900.6% during the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company's stock worth $291,000 after acquiring an additional 32,700 shares during the period. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Price Performance

Shares of Scholar Rock stock traded down $0.52 during trading hours on Friday, reaching $32.84. 1,129,184 shares of the company's stock were exchanged, compared to its average volume of 1,173,533. The business has a fifty day moving average of $37.94 and a two-hundred day moving average of $32.72. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $3.11 billion, a P/E ratio of -13.97 and a beta of 0.59. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $40.86.

Insider Activity at Scholar Rock

In other news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the sale, the director now owns 30,319 shares of the company's stock, valued at approximately $1,043,579.98. The trade was a 3.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jing L. Marantz sold 5,655 shares of Scholar Rock stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the sale, the insider now owns 67,200 shares of the company's stock, valued at approximately $2,970,240. This represents a 7.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 299,772 shares of company stock valued at $11,245,798. Corporate insiders own 19.20% of the company's stock.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.